Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Its pipeline includes AP-PA02, an inhaled phage targeting Pseudomonas aeruginosa in cystic fibrosis, and AP-SA02, targeting Staphylococcus aureus. The company has completed three Phase 2 randomized, double-blind, placebo-controlled clinical trials and operates a cGMP-compliant bacteriophage manufacturing facility in Los Angeles.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001104659-26-034532 | EDGAR | 78K words |
| 2025-03-21 | 2024-12-31 | 0001558370-25-003406 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001558370-24-003706 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0001558370-23-004014 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001558370-22-003845 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001558370-21-003202 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001558370-20-002943 | EDGAR | — |
| 2019-03-25 | 2018-12-31 | 0001144204-19-015711 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001144204-18-014652 | EDGAR | — |
| 2017-03-27 | 2016-12-31 | 0001144204-17-016833 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-110383 | EDGAR | 24K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011235 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007765 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015530 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001558370-24-012061 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007068 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019036 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014701 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009372 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017141 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001558370-22-013269 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001558370-22-008532 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001104659-26-039180 | EDGAR | 1K words |
| 2026-03-25 | 0001104659-26-034523 | EDGAR | — |
| 2026-03-19 | 0001104659-26-031715 | EDGAR | — |
| 2026-02-23 | 0001104659-26-018333 | EDGAR | — |
| 2026-01-26 | 0001104659-26-006446 | EDGAR | — |
| 2026-01-13 | 0001104659-26-003076 | EDGAR | — |
| 2025-12-01 | 0001104659-25-117387 | EDGAR | — |
| 2025-11-12 | 0001104659-25-110351 | EDGAR | — |
| 2025-10-22 | 0001104659-25-101447 | EDGAR | — |
| 2025-09-11 | 0001104659-25-089150 | EDGAR | — |
445 total filings indexed. 413 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000921114 |
| Ticker | ARMP |
| Exchange | NYSE |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | WA |
| Headquarters | Los Angeles, California |
| Website | https://www.armatapharma.com |
| Listed | 1994-05-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report